Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
Why Vir Biotechnology Stock Vaulted Higher Today
03:26pm, Tuesday, 12'th Jan 2021
The biotech announced updates about collaborations with two big partners.
Our Covid antibody treatment will work against new strains: Vir CEO
02:26pm, Tuesday, 12'th Jan 2021
CNBC's Meg Tirrell discusses coronavirus antibody treatments in light of new Covid strains across the world with Vir CEO George Scangos at the J.P. Morgan Healthcare Conference.
– First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research –
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
03:00am, Tuesday, 12'th Jan 2021
SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiat
Are Options Traders Betting on a Big Move in in Vir Biotechnology (VIR) Stock?
12:02pm, Tuesday, 22'nd Dec 2020
Investors need to pay close attention to in Vir Biotechnology (VIR) stock based on the movements in the options market lately.
Vir, GSK's experimental COVID-19 treatment moves into a Phase 3 clinical trial
09:12am, Friday, 18'th Dec 2020
Shares of Vir Biotechnology Inc. gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline said they started dosing patients in a late-stage clinical trial for an exper
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
04:01pm, Thursday, 17'th Dec 2020
– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 –
Vir Biotechnology Appoints Jeffrey Hatfield to its Board of Directors
08:00am, Thursday, 10'th Dec 2020
SAN FRANCISCO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeffrey Hatfield, an accomplished industry executive with more than three deca
Vaccines and Approved Antibodies Dim Vir Biotechnology's Covid Opportunity, Analyst Says
10:11am, Friday, 04'th Dec 2020
Competitors have already gotten emergency use authorizations from regulators and booked orders for their antibody treatments.
2 Ultra-Risky Coronavirus Stocks That Could Make You Filthy Rich
06:45am, Tuesday, 01'st Dec 2020
They'll be later to market than rivals. But if their product candidates are stronger, investors may reap rewards.
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results
04:01pm, Tuesday, 10'th Nov 2020
SAN FRANCISCO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provid
Vir Biotechnology: Small-Cap Player That Lets Others Do The Heavy Lifting
08:31am, Saturday, 07'th Nov 2020
Vir Biotechnology has a deep pipeline across many disease segments, reducing concentration risk in the portfolio and expanding commercial reach. The company has key collaborations with large players,
– Manuscript highlights the importance of molecular surveillance of SARS-CoV-2 immune evasion and rational design of vaccines and antibody therapies for COVID-19 – – Manuscript highlights the im
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020
04:01pm, Tuesday, 27'th Oct 2020
SAN FRANCISCO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announ
